Pfizer’s Metsera deal could spark more M&A for pharmas ‘tiptoeing into obesity’news2025-09-25T14:58:48+00:00September 25th, 2025|Endpoints News|
UK government reveals £50M R&D fund as it attempts to assuage drugmakers’ concerns news2025-09-25T13:59:06+00:00September 25th, 2025|Endpoints News|
Epic embraces the newfound attention of its AI toolsnews2025-09-25T13:00:26+00:00September 25th, 2025|Endpoints News|
Merck KGaA CEO Belén Garijo to leave next May, when electronics unit leader will take the helmnews2025-09-25T11:25:21+00:00September 25th, 2025|Endpoints News|
Thyme Care hits $1B valuation in latest funding roundnews2025-09-25T11:00:02+00:00September 25th, 2025|Endpoints News|
PepGen seeks funds on the back of early-stage data in muscle wasting diseasenews2025-09-25T10:28:11+00:00September 25th, 2025|Endpoints News|
Hansa’s kidney transplant drug succeeds in Phase 3 trial in USnews2025-09-25T08:36:14+00:00September 25th, 2025|Endpoints News|
Biopharma industry tries to parse impact of Trump crackdown on H-1B visasnews2025-09-24T20:12:09+00:00September 24th, 2025|Endpoints News|
Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this yearnews2025-09-24T20:02:25+00:00September 24th, 2025|Endpoints News|
AstraZeneca files to try to bring IRA fight to Supreme Court news2025-09-24T19:25:34+00:00September 24th, 2025|Endpoints News|
